Factor D, when preincubated with platelet suspensions, at concentrations as low as 1.2 micrograms/ml, inhibited thrombin-induced platelet aggregation. No inhibition of collagen or arachidonic acid-induced platelet aggregation was found. Inhibition occurred, but to a lesser extent, when thrombin and factor D were added to platelets at the same time. No inhibition occurred when factor D was added after thrombin. Thrombin was able to overcome inhibition by factor D by increasing its concentration. Diisopropyl-phosphorofluoridate-inactivated factor D also inhibited thrombin-induced platelet aggregation so that enzymatic activity of factor D was not required for inhibition. Factor D absorbed with hirudin coupled to Sepharose 6B showed no decrease in inhibitory capacity. 125I-Factor D bound to platelets in a manner suggesting an equilibrium reaction similar to thrombin. At low factor D input, binding was linear, whereas at higher input, binding began to approach saturation. Binding of 125I-labeled thrombin to platelets was inhibited by factor D. Analysis of these data show that factor D does not alter the total number of thrombin molecules which bind to the platelet surface at saturation. However, the dissociation constant for thrombin is altered from 2.78 to 6.90 nM in the presence of factor D (20 micrograms/ml). Factor D is thus a competitive inhibitor of thrombin binding, although the affinity of factor D for the platelet thrombin receptor is much less than that of thrombin. These phenomena occur at physiologic concentrations of factor D. Therefore, factor D may function in vivo as an inhibitor of platelet aggregation.
A E Davis 3rd, D M Kenney
Title and authors | Publication | Year |
---|---|---|
Complement in Hemolysis- and Thrombosis- Related Diseases
S Luo, D Hu, M Wang, PF Zipfel, Y Hu |
Frontiers in immunology | 2020 |
Complement links platelets to innate immunity
H Nording, HF Langer |
Seminars in Immunology | 2018 |
Complement-coagulation crosstalk on cellular and artificial surfaces
R Wiegner, S Chakraborty, M Huber-Lang |
Immunobiology | 2016 |
Protective Role for Properdin in Progression of Experimental Murine Atherosclerosis
T Steiner, L Francescut, S Byrne, T Hughes, A Jayanthi, I Guschina, J Harwood, K Cianflone, C Stover, S Francis, A Zernecke |
PloS one | 2014 |
Current Topics in Complement II
JD Lambris |
2008 | |
Platelet mediated complement activation.
Peerschke EI, Yin W, Ghebrehiwet B |
Advances in experimental medicine and biology | 2008 |
Proteases
MA Phillips, RJ Fletterick |
Current Opinion in Structural Biology | 1992 |
The Complement System
A Agostoni, M Cicardi, M Gardinali, L Bergamaschini |
International journal of immunopathology and pharmacology | 1992 |
Membrane Defenses Against Attack by Complement and Perforins
CJ Parker |
1992 | |
Regulation of the activity of platelet-bound C3 convertase of the alternative pathway of complement by platelet factor H
DV Devine, WF Rosse |
Proceedings of the National Academy of Sciences | 1987 |
The role of complement in immune clearance of blood cells
UE Nydegger, MD Kazatchkine |
Springer Seminars in Immunopathology | 1983 |
Platelets and the Inflammatory Response
BB Weksler |
Clinics in Laboratory Medicine | 1983 |
The Physiology of Hemostasis
D Ogston |
1983 | |
SURFACE PROTEIN ABNORMALITIES IN LYMPHOCYTES AND PLATELETS FROM PATIENTS WITH WISKOTT-ALDRICH SYNDROME
R Parkman, DM Kenney, E Remold-O'Donnell, S Perrine, FS Rosen |
The Lancet | 1981 |
Association of alternative complement pathway components with human blood platelets: Secretion and localization of factor D and β1H globulin
DM Kenney, AE Davis |
Clinical Immunology and Immunopathology | 1981 |